I can't think of a good example off-hand but have wondered what if one product (same mechanism) had better safety/tolerability or was more convenient either via dosing or route of administration. Could it break Orphan exclusivity?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.